Ampreloxetine

DB15348InvestigationalSmall molecule

Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter
Curator reviewed
Formula / weight: C₁₈H₁₈F₃NO · 321.343 g/mol (avg)
Code names: TD-9855

Resolves to

Compound

UNII19997EZ42ICAS1227056-84-9

Structure

InChIKeyTZIALEBTHQWNAO-UHFFFAOYSA-NSMILESFC1=CC(F)=C(OCC2=CC=CC=C2C2CCNCC2)C(F)=C1

Targets

P23975SLC6A2P31645SLC6A4

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ampreloxetine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account